New heart pump aims to make risky angioplasty safer
Disease control
Not yet recruiting
This trial compares a new temporary heart pump called VentriCure with standard ECMO support in people with coronary artery disease undergoing high-risk angioplasty. The study includes 220 patients whose hearts are weak or who have severe heart failure. The goal is to see if Ventr…
Phase: NA • Sponsor: Life Shield Medical Technology Co., LTD • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC